Could an allergy drug stop Liver-Related itching?

NCT ID NCT04256759

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small study tested dupilumab (Dupixent), a drug used for allergies and eczema, in 9 adults with moderate to severe chronic itching from liver disease. Participants received injections every 2 weeks for 18 weeks. The goal was to see if itching scores improved. Because it was an early, open-label trial with no comparison group, results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Dupilumab (Dupixent) injection

What this could lead to

If it works, this could point toward a new treatment for severe itching caused by liver disease.

What could go wrong

This is a very small, early-phase study with only 9 participants and no placebo group. Results may not apply to everyone, and the drug may not work or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRURITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic Florida

    Jacksonville, Florida, 32224, United States